Document Type : Original Research


Dept. of Pathology, Shahid Beheshti University of Medical Sciences, Tehran, Iran


Background and objective: EGFR and HER-2 are two members of ERbB/HER family of Type I Transmembrane growth factor receptors. Cox2 is an enzyme responsible for the conversion of arachidonic acid to prostaglandins, which has a major role in angiogenesis and can modelate tumor growth. The aim of this study was to determine the level of expression of EGFR, HER-2 and Cox2 in colorectd cancer.
Material and Methods: IHC study was performed in paraffin-embedded blocks of 47 patients underwent colectomy due to colorectal cancer in Modarres Hospital, Tehran, Iran from 2008 to 2009. Three separated pathologists analyzed the slides after complete IHC staining for EGFR, HER-2 and COX-2.
Results: EGFR, HER-2 and Cox2 revealed over expression in colorectal cancer as 80.9%, 25.5% and 72.4% respectively, EGFR revealed no statistically significant association with clinicopathologic parameters, but Cox2 overexpression exhibited statistically significant association with higher stages tumors (III, IV) (P value: 0.037)  and tumor with lymph node metastasis(P= 0.005). On the other hand, HER2 overexpression showed statistically significant association with lower grade (well and moderately differentiation) tumors (P= 0.042). 
Conclusion: According to over expression of three markers, EGFR, HER-2, and COX-2 in colorectal cancers, using drugs that act against these receptors and investigation of survival improvement of patients with these drugs in other studies are recommended.


  1. Antonacopoulou AG, Tsamandas AC, Petsas T, Liava A, Scopa CD, Papavassiliou AG, et al. EGFR, HER-2 and COX-2 levels in colorectal cancer. Histopathology 2008;53(6):698-706.
  2. Rosai J. Rosai and ackerman surgical pathology. 9th  ed. New York:Mosby; 2004.
  3.  Arteage CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002;29:3-9.
  4. Berchuck A, Rodriguez G, Kamel A, Soper JT, Clarke-Pearson DL, Bast RC Jr. Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina. Obstet Gynecol 1990;76:381-7.
  5.  Williams CS, Mann M, DuBois RN.  The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18(55): 7908-16.
  6.  Cunningham MP, Essapen S, Thomas H, Green M, Lovell DP, Topham C, et al. Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. Int J Oncol. 2006;28(2):329-35.
  7.  Molaei M, Pejhan S, Nayer BN, Moradi A, Ghiasi S, Zali MR. Human epidermal growth factor receptor-2 family in colorectal adenocarcinoma: correlation with survival and clinicopathological findings. Eur J Gastroenterol Hepatol. 2009;21(3):289-93.
  8.  McKay JA, Murray LJ, Curran S, Ross VG, Clark C, Murray GI, et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumors and lymph node metastases. Eur J Cancer. 2002;38(17):2258-64.
  9. Moorghen M, Ince P, Finney KJ, Watson AJ, Harris AL. Epidermal growth factor receptors in colorectal carcinoma. Anticancer Res. 1990;10(3):605-11.
  10. Koenders PG, Peters WH, Wobbes T, Beex LV, Nagengast FM, Benraad TJ. Epidermal growth factor receptor levels are lower in carcinomatous than in normal colorectal tissue. Br J Cancer. 1992;65(2):189-92.
  11. Kumar V. Abbas A, Fausto N. Robbins and Cotran Pathologic Basis of Diseases. 7th  ed. New York:Saunders;2007.
  12. Soliman AS, Bondy ML, El-Badawy SA, Mokhtar N, Eissa S, Bayoumy S,  et al. Contrasting molecular pathology of colorectal carcinoma in Egyptian and Western patients. Br J Cancer 2001;85(7):1037-46.
  13. Arnaout AH, Dawson PM, Soomro S, Taylor P, Theodorou NA, Feldmann M, et al. HER2 oncoprotein expression in colorectal adenocarcinoma: an immunohistochemical study using three different antibodies. J Clin Pathol 1992;45(8):726-7.
  14. Mattoon D, Klein P, Lemmon MA, Lax I, Schlessinger J. The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function. Proc Natl Acad Sci U S A. 2004;101(4):923-8.
  15. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer cell 2004;5(5):455-63.
  16. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001;61(23):8492-97.